文献速递前列腺癌

磁共振靶向穿刺为何漏检临床显著前列腺癌

Why Does Magnetic Resonance Imaging-Targeted Biopsy Miss Clinically Significant Cancer?
PubMed 文献 · J Urol · 2021-08-26

该回顾性分析基于2007至2019年前瞻性队列中2103例接受经直肠MRI靶向融合穿刺联合系统12针穿刺的患者,其中41例(1.9%)为MRI靶向穿刺漏检而系统穿刺检出GG≥3级癌症。漏检原因以病灶靶向误差为主(51.2%),其次为MRI不可见病灶(40.5%)和放射科医生漏判MRI病灶(7.1%)。较低的PI-RADS评分与MRI靶向穿刺漏检临床显著癌症相关。

要点

  • MRI靶向穿刺漏检临床显著癌虽罕见(1.9%),但多因病灶靶向误差所致。
  • 部分患者存在MRI不可见病灶,无法被靶向平台命中。
  • 高PSA但低PI-RADS评分提示可能存在MRI不可见病灶。

核心结论

  • MRI靶向穿刺漏检临床显著癌不常见,多数漏检归因于病灶靶向误差,强调软件融合平台精准配准与靶向的重要性。
  • 部分患者存在MRI不可见病灶,无法被MRI靶向平台靶向;高PSA伴低PI-RADS评分提示此类病灶可能。

研究设计与样本

  • 回顾性分析嵌入前瞻性研究,比较经直肠MRI靶向融合穿刺与系统12针穿刺的癌症检出率。
  • 2007至2019年共2103例因PSA升高、直肠指检异常或影像可疑前列腺癌的患者接受同次MRI靶向联合系统穿刺。
  • MRI靶向穿刺漏检定义为系统穿刺发现GG≥3级癌症而MRI靶向穿刺为GG≤2级或无癌。
  • 对MRI及MRI靶向穿刺实时屏幕截图进行回顾分析以判定漏检原因。
  • 采用多变量逻辑回归比较漏检患者与GG匹配的靶向检出患者的基线特征。

主要发现

  • 41例(1.9%)被归类为MRI靶向穿刺漏检。
  • 漏检原因中病灶靶向误差21例(51.2%),MRI不可见病灶17例(40.5%),放射科医生漏判MRI病灶3例(7.1%)。
  • 逻辑回归分析显示较低PI-RADS评分与MRI靶向穿刺漏检临床显著癌相关。

临床怎么用

  • 使用软件融合平台时应重视精准配准与靶向操作以减少漏检。
  • 对于高PSA但PI-RADS评分低的患者,应警惕MRI不可见病灶可能,系统穿刺仍不可省略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Multiple studies demonstrate magnetic resonance imaging (MRI)-targeted biopsy detects more clinically significant cancer than systematic biopsy; however, some clinically significant cancers are detected by systematic biopsy only. While these events are rare, we sought to perform a retrospective analysis of these cases to ascertain the reasons that MRI-targeted biopsy missed clinically significant cancer which was subsequently detected on systematic prostate biopsy. MATERIALS AND METHODS: Patients were enrolled in a prospective study comparing cancer detection rates by transrectal MRI-targeted fusion biopsy and systematic 12-core biopsy. Patients with an elevated prostate specific antigen (PSA), abnormal digital rectal examination, or imaging findings concerning for prostate cancer underwent prostate MRI and subsequent MRI-targeted and systematic biopsy in the same setting. The subset of patients with grade group (GG) ≥3 cancer found on systematic biopsy and GG ≤2 cancer (or no cancer) on MRI-targeted biopsy was classified as MRI-targeted biopsy misses. A retrospective analysis of the MRI and MRI-targeted biopsy real-time screen captures determined the cause of MRI-targeted biopsy miss. Multivariable logistic regression analysis compared baseline characteristics of patients with MRI-targeted biopsy misses to GG-matched patients whose clinically significant cancer was detected by MRI-targeted biopsy. RESULTS: Over the study period of 2007 to 2019, 2,103 patients met study inclusion criteria and underwent combined MRI-targeted and systematic prostate biopsies. A total of 41 (1.9%) men were classified as MRI-targeted biopsy misses. Most MRI-targeted biopsy misses were due to errors in lesion targeting (21, 51.2%), followed by MRI-invisible lesions (17, 40.5%) and MRI lesions missed by the radiologist (3, 7.1%). On logistic regression analysis, lower Prostate Imaging-Reporting and Data System (PI-RADSTM) score was associated with having clinically significant cancer missed on MRI-targeted biopsy. CONCLUSIONS: While uncommon, most MRI-targeted biopsy misses are due to errors in lesion targeting, which highlights the importance of accurate co-registration and targeting when using software-based fusion platforms. Additionally, some patients will harbor MRI-invisible lesions which are untargetable by MRI-targeted platforms. The presence of a low PI-RADS score despite a high PSA is suggestive of harboring an MRI-invisible lesion.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Williams C, Ahdoot M, Daneshvar MA, et al. Why Does Magnetic Resonance Imaging-Targeted Biopsy Miss Clinically Significant Cancer? J Urol. 2021. PMID: 34433302. doi:10.1097/JU.0000000000002182

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。